Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib

Jorge E Cortes, Hanna J Khoury, Hagop M Kantarjian, Jeff H Lipton, Dong-Wook Kim, Philippe Schafhausen, Ewa Matczak, Eric Leip, Kay Noonan, Tim H Brümmendorf, Carlo Gambacorti-Passerini, Jorge E Cortes, Hanna J Khoury, Hagop M Kantarjian, Jeff H Lipton, Dong-Wook Kim, Philippe Schafhausen, Ewa Matczak, Eric Leip, Kay Noonan, Tim H Brümmendorf, Carlo Gambacorti-Passerini

Abstract

Bosutinib is an Src/Abl tyrosine kinase inhibitor (TKI) indicated for adults with Ph+ chronic myeloid leukemia (CML) resistant/intolerant to prior TKIs. This long-term update of an ongoing phase 1/2 study evaluated the efficacy and safety of third-/fourth-line bosutinib in adults with chronic phase (CP) CML. Median durations of treatment and follow-up were 8.6 (range, 0.2-87.7) months and 32.7 (0.3-93.3) months, respectively. Cumulative confirmed complete hematologic response (cCHR) and major cytogenetic response (MCyR) rates were 74% (95% CI, 65-81%) and 40% (31-50%), respectively; Kaplan-Meier (K-M) probability of maintaining cCHR or MCyR at 4 years was 63% (95% CI, 50-73%) and 69% (52-81%). Cumulative incidence of on-treatment disease progression (PD)/death at 4 years was 24% (95% CI, 17-33%); K-M 4-year overall survival was 78% (68-85%). Baseline Ph+ cells ≤35 vs. ≥95% was prognostic of MCyR and CCyR by 3 and 6 months, increased baseline basophils was prognostic of PD/death, and no prior response to second-line TKI was prognostic of death. Common adverse events included diarrhea (83%), nausea (48%), vomiting (38%), and thrombocytopenia (39%). Bosutinib demonstrates durable efficacy and a toxicity profile similar to previous bosutinib studies in CP CML patients resistant/intolerant to multiple TKIs, representing an important treatment option for patients in this setting. This trial is registered at www.clinicaltrials.gov (NCT00261846). Am. J. Hematol. 91:1206-1214, 2016. © 2016 Wiley Periodicals, Inc.

© 2016 Wiley Periodicals, Inc.

Figures

Figure 1
Figure 1
Cumulative incidence of response and duration of response. (A) Cumulative incidence of CHR adjusting for the competing risk of treatment discontinuation without the event; (B) duration of CHR among responders. (C) Cumulative incidence of MCyR adjusting for the competing risk of treatment discontinuation without the event; (D) duration of MCyR among responders. CHR = complete hematologic response; CI = confidence interval; D = dasatinib; I = intolerant; IM = imatinib; K–M = Kaplan–Meier; MCyR = major cytogenetic response; N = nilotinib; NE = not evaluable; R = resistant.
Figure 2
Figure 2
Percentage of patients with TEAEs occurring in year 1 and newly occurring in years 2, 3, and 4 in ≥10% of patients overall (any grade). AE = adverse event; ALT = alanine aminotransferase; TEAE = treatment‐emergent adverse event. Denominators are the number of patients on treatment during the specific years (note: the incidence of certain TEAEs appears higher in later years compared with previous years due to a lower number of patients on treatment: pleural effusion [year 1, n = 6/119; year 2, n = 6/50; year 3, n = 1/39; year 4, n = 5/32]; increased blood creatinine [year 1, n = 8/119; year 2, n = 2/50; year 3, n = 1/39; year 4, n = 4/32]; cardiac AEs [year 1, n = 8/119; year 2, n = 4/50; year 3, n = 1/39; year 4, n = 3/32]). 1 year = 365.25 days. Newly occurring TEAEs were defined as those MedDRA preferred terms (PTs) not experienced by the same patient previously for patients on treatment during a given year. *Includes all PTs under the high‐level group terms cardiac arrhythmias, pericardial disorders, and heart failures under the cardiac disorders system organ class (SOC) and the following PTs: cardiac death, sudden cardiac death, sudden death, decreased ejection fraction, abnormal electrocardiogram QT interval, prolonged electrocardiogram QT, congenital long QT syndrome.

References

    1. Jain P, Kantarjian H, Cortes J. Chronic myeloid leukemia: Overview of new agents and comparative analysis. Curr Treat Options Oncol 2013;14:127–143.
    1. Deininger MW, Kopecky KJ, Radich JP, et al. Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: Results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia. Br J Haematol 2014;164:223–232.
    1. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR–ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031–1037.
    1. Hochhaus A, O'Brien SG, Guilhot F, et al. Six‐year follow‐up of patients receiving imatinib for the first‐line treatment of chronic myeloid leukemia. Leukemia 2009; 23:1054–1061.
    1. Jabbour E, Kantarjian HM, Saglio G, et al. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3‐year follow‐up from a randomized phase 3 trial (DASISION). Blood 2014;123:494–500.
    1. Shah NP, Guilhot F, Cortes JE, et al. Long‐term outcome with dasatinib after imatinib failure in chronic‐phase chronic myeloid leukemia: Follow‐up of a phase 3 study. Blood 2014;123:2317–2324.
    1. Hughes TP, Lipton JH, Spector N, et al. Deep molecular responses achieved in patients with CML‐CP who are switched to nilotinib after long‐term imatinib. Blood 2014;124:729–736.
    1. Hughes TP, Saglio G, Kantarjian HM, et al. Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. Blood 2014;123:1353–1360.
    1. Jabbour E, Cortes JE, Ghanem H, et al. Targeted therapy in chronic myeloid leukemia. Expert Rev Anticancer Ther 2008;8:99–110.
    1. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia—version 1, 2015. . Accessed July 13, 2016.
    1. Ramirez P, DiPersio JF. Therapy options in imatinib failures. Oncologist 2008;13:424–434.
    1. Cortes JE, Kantarjian HM, Brummendorf TH, et al. Safety and efficacy of bosutinib (SKI‐606) in chronic phase Philadelphia chromosome‐positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood 2011;118:4567–4576.
    1. Gambacorti‐Passerini C, Brummendorf TH, Kim DW, et al. Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24‐month follow‐up. Am J Hematol 2014;89:732–742.
    1. Khoury HJ, Cortes JE, Kantarjian HM, et al. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. Blood 2012;119:3403–3412.
    1. Redaelli S, Piazza R, Rostagno R, et al. Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib‐resistant BCR/ABL mutants. J Clin Oncol 2009;27:469–471.
    1. Giles FJ, O'Dwyer M, Swords R. Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Leukemia 2009;23:1698–1707.
    1. Puttini M, Coluccia AM, Boschelli F, et al. In vitro and in vivo activity of SKI‐606, a novel Src‐Abl inhibitor, against imatinib‐resistant Bcr–Abl+ neoplastic cells. Cancer Res 2006;66:11314–11322.
    1. Remsing Rix LL, Rix U, Colinge J, et al. Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells. Leukemia 2009;23:477–485.
    1. Bartolovic K, Balabanov S, Hartmann U, et al. Inhibitory effect of imatinib on normal progenitor cells in vitro . Blood 2004;103:523–529.
    1. Konig H, Holyoake TL, Bhatia R. Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src/Abl kinase inhibitor SKI‐606. Blood 2008;111:2329–2338.
    1. Gambacorti‐Passerini C, Cortes JE, Lipton JH, et al. Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia. Am J Hematol 2014;89:947–953.
    1. Kantarjian HM, Cortes JE, Kim DW, et al. Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors. Blood 2014;123:1309–1318.
    1. . NCT01903733. .
    1. Garg RJ, Kantarjian H, O'Brien S, et al. The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: Long‐term follow‐up. Blood 2009;114:4361–4368.
    1. Giles FJ, Abruzzese E, Rosti G, et al. Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy. Leukemia 2010;24:1299–1301.
    1. Ibrahim AR, Paliompeis C, Bua M, et al. Efficacy of tyrosine kinase inhibitors (TKIs) as third‐line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapy. Blood 2010;116:5497–5500.
    1. Cortes JE, Kim DW, Pinilla‐Ibarz J, et al. A phase 2 trial of ponatinib in Philadelphia chromosome‐positive leukemias. N Engl J Med 2013;369:1783–1796.
    1. Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006;108:1809–1820.
    1. Redaelli S, Mologni L, Rostagno R, et al. Three novel patient‐derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors. Am J Hematol 2012;87:E125–E128.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir